Siren Biotechnology

Siren Biotechnology is a private, pre-revenue company creating a new therapeutic modality that merges AAV gene delivery with cytokine immunotherapy to fight solid tumors. The company has transitioned to a clinical-stage entity with its first IND cleared by the FDA in early 2026 and its lead program, SRN-101, receiving Fast Track Designation for recurrent high-grade glioma. Siren's strategy is to first address the high-unmet-need area of brain cancer as a proving ground for its platform, with the long-term vision of establishing AAV immuno-gene therapy as a cornerstone treatment for any solid tumor. The company is leveraging its scientific expertise in viral technology and immuno-oncology to overcome historical challenges in these fields.

AAV immuno-gene therapy platform combining AAV vector gene delivery with localized, sustained expression of immunomodulatory cytokines in the tumor microenvironment.

Siren competes in the broad solid tumor immunotherapy space, which includes checkpoint inhibitors, cellular therapies (CAR-T, TILs), oncolytic viruses, and other cytokine therapies. Its direct competitors are other companies developing gene therapies or viral vectors for in-situ immune activation in oncology. Differentiation lies in the specific combination of AAV delivery with sustained local cytokine expression to reprogram the tumor microenvironment.